Tests Jarlsberg cheese with calcium and vitamin D for bone health
Tests daily Jarlsberg cheese with calcium and vitamin D in adults over 55 with osteopenia.
Plain-language title generated from the registry record
Registry title: Profylactic Treatment for Patients in Risk Osteoporosis
Key facts
- Where
- Skjetten, NorwaySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men and women over 55 with low bone density (osteopenia) to test whether daily Jarlsberg cheese, added to calcium and vitamin D, helps their bones.
- Age
- 55 to 85 years
- Sex
- Women and men
- Disease stage
- Osteopenia: a bone density T-score below 0.0 but larger than -2.5.
- Earlier treatment
- Cannot be on active bone-thinning-prevention (antiresorptive) or anabolic bone treatment. Cannot have taken corticosteroids or other immunosuppressive drugs in the last 3 weeks. Cannot have been in another drug trial in the last six weeks.
Main reasons for not taking part
- Eating disorder
- Known gastrointestinal disorder
- Abnormal liver or kidney function
- Diabetes type I, or type II without sufficient control
- Verified cancer or known milk product allergy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 85 years old?
Source: NCT05787808, who can take part
Where in Norway
- MeddocSkjetten, NorwayContact: Stig Larsen, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Meddoc
- Trial code
- NCT05787808
- Record updated
- 29 September 2025
- Original description
The aim is to compare the daily intake of Calsium (Ca) + vitamin D with and without daily optimal efficacy dose (OED) of Jarlsberg on Bone Mineral Density (BMD) and bone markers (BM) to Osteopeni patients (OP).Read full original descriptionShow less
The Effect on Bone Marker and Body Mineral Density (BMD) of Daily Jarlsberg Cheese Intake in Risk Patient for Osteoporosis
The aim is to compare the daily intake of Calsium (Ca) + vitamin D with and without daily optimal efficacy dose (OED) of Jarlsberg on Bone Mineral Density (BMD) and bone markers (BM) to Osteopeni patients (OP).
* The study population consists of OP-patients of post-menopausal women and men above 55 years of age. OP patients are defined as patients with a T-score below 0.0, but larger than -2.5. * The study will be performed as a randomized, single-blinded Norwegian multicentre trial with stratified semi-cross-over design with gender and site as stratification factors. The OP-patients included in the study will be allocated to one of the two treatment groups by block randomization with random block size between 2 and 6. * Women in post-menopausal age have a daily OED Jarlsberg of 45 gram and men in the same age interval have a daily OED of 55 gram. * The main response variable will be the change in Bone Mineral Density (BMD),total Osteocalcin (tOC) and different bone markers (BM). * Participants, who fulfil the inclusion criteria, do not meet any of the exclusion criteria and willing to give informed consent to participate will be included and receiving 40µg vitamin D and 500 mg Ca tablets per day, but asked not to eat Jarlsberg cheese the following week. During this week demographic data, bloodsampling for measurement of Osteocalcin and BM and diet registration will be performed.In the clinical study, all the included patients will continue with Ca+ vitamin D, but half of the patient will additionally receive daily OED of Jarlsberg cheese. After 16 weeks, all the patients will receive both Ca+vitamin D and OED of Jarlsberg for addionally 16 weeks. The total duration of the study will be 32 weeks for the patients initially allocated to Jarlsberg and 48 weeks for those allocated only to Ca+vitamin D. The patients will be investigated initially and every 16 weeks. * A total of 30 patients will be included in each of the two groups.
Inclusion: Osteopeni patients (OP) of both genders above 55 years of age. OPs are defined as patients with T-score below 0.0 but larger than -2.5.
Exclusion: • Eating disorder; Known gastrointestinal disorder; Abnormal liver or kidney function; Diabetes mellitus type I; Diabetes type II without sufficient control; Suffering from verified cancer; Under systemic treatment with corticosteroids or other immunosuppressive drugs the last 3 weeks before start of the trial treatment; Under active antiresorptive treatment or anabolic treatment; Participating in another clinical trial with pharmaceuticals the last six weeks before start of this trial treatment; Known milk product allergy; Not able to understand information; Do not want or not able to give written consent to participate in the study.